UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934
(Amendment No. )* 

Moderna, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share
(Title of Class of Securities)

60770K107
(CUSIP Number)

December 6, 2018
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)
☐ Rule 13d-1(c)
☒ Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
1. Name of Reporting Person
   AstraZeneca PLC

2. Check the Appropriate Box if a Member of a Group (See Instructions)
   (a) □
   (b) ☒ (Joint filers)

3. SEC Use Only

4. Citizenship or Place of Organization
   United Kingdom

5. Sole Voting Power
   25,499,325 shares(1)

6. Shared Voting Power
   0 shares

7. Sole Dispositive Power
   25,499,325 shares(2)

8. Shared Dispositive Power
   0 shares

9. Aggregate Amount Beneficially Owned by Each Reporting Person
   25,499,325 shares(3)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) □

11. Percent of Class Represented by Amount in Row (9)
    7.75%(4)

12. Type of Reporting Person (See Instructions)
    CO

---

(1) Represents shares directly held by Zeneca Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Zeneca Inc. may each be deemed to have sole voting and dispositive power over the shares.

(2) See footnote 1.

(3) See footnote 1.

(4) The percentage ownership was calculated based on 328,948,088 shares of the issuer’s common stock outstanding as of December 11, 2018, upon closing of the issuer’s initial public offering, as reported in the issuer’s prospectus dated December 6, 2018 (the “Final Prospectus”) filed with the Securities and Exchange Commission (the “SEC”) on December 7, 2018 pursuant to Rule 424(b)(4) under the Securities Act of 1933, as amended (the “Securities Act”).
1. Name of Reporting Person  
   Zeneca Inc.

2. Check the Appropriate Box if a Member of a Group (See Instructions)  
   (a) ☐  
   (b) ☒ (Joint filers)

3. SEC Use Only

4. Citizenship or Place of Organization  
   Delaware

5. sole Voting Power  
   25,499,325 shares(5)

6. Shared Voting Power  
   0 shares

7. Sole Dispositive Power  
   25,499,325 shares(6)

8. Shared Dispositive Power  
   0 shares

9. Aggregate Amount Beneficially Owned by Each Reporting Person  
   25,499,325 shares(7)

10. Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ☐

11. Percent of Class Represented by Amount in Row (9)  
    7.75%(8)

12. Type of Reporting Person (See Instructions)  
    CO

---

(5) See footnote 1.  
(6) See footnote 1.  
(7) See footnote 1.  
(8) See footnote 4.
Item 1.
(a) Name of Issuer
Moderna, Inc.

(b) Address of Issuer’s Principal Executive Offices
200 Technology Square
Cambridge, MA 02139

Item 2.
(a) Name of Person Filing
See response to 2(c)

(b) Address of Principal Business Office or, if none, Residence
See response to 2(c)

(c) Citizenship
This statement is filed on behalf of:

AstraZeneca PLC
1 Francis Crick Avenue
Cambridge Biomedical Campus
Cambridge CB2 0AA
United Kingdom
Citizenship: United Kingdom

Zeneca Inc.
1800 Concord Pike
Wilmington, Delaware, 19803
Citizenship: Delaware

(d) Title of Class of Securities
Common Stock, par value $0.0001 per share

(e) CUSIP Number
60770K107

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) [ ] Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) [ ] An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

(f) [ ] An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

(g) [ ] A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

(h) [ ] A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) [ ] A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) [ ] A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J);

(k) [ ] Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution: ________________________________
Item 4. Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

(a) Amount beneficially owned:
25,499,325 shares

(b) Percent of class:
7.75%. The percentage stated herein is based on 328,948,088 shares of the issuer’s common stock outstanding as of December 11, 2018, upon closing of the issuer’s initial public offering, as reported in the Final Prospectus filed with the SEC on December 7, 2018 pursuant to Rule 424(b)(4) under the Securities Act.

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:
   AstraZeneca PLC: 25,499,325 shares
   Zeneca Inc.: 25,499,325 shares

(ii) Shared power to vote or to direct the vote:
   AstraZeneca PLC: 0 shares
   Zeneca Inc.: 0 shares

(iii) Sole power to dispose or to direct the disposition of:
   AstraZeneca PLC: 25,499,325 shares
   Zeneca Inc.: 25,499,325 shares

(iv) Shared power to dispose or to direct the disposition of:
   AstraZeneca PLC: 0 shares
   Zeneca Inc.: 0 shares

Zeneca Inc., a wholly owned subsidiary of AstraZeneca PLC, is the direct record holder of all 25,499,325 shares reported herein. Each of Zeneca Inc. and AstraZeneca PLC may be deemed to have sole voting and dispositive power with respect to such shares.

Item 5. Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☐

Item 6. Ownership of More than Five Percent on Behalf of Another Person
Not applicable.

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person
Not applicable.

Item 8. Identification and Classification of Members of the Group
Not applicable.

Item 9. Notice of Dissolution of Group
Not applicable.
Item 10. Certifications
Not applicable.

Material Filed as Exhibits

Exhibit 99 Joint Filing Agreement between AstraZeneca PLC and Zeneca Inc.

Signatures
After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

January 30, 2019

AstraZeneca PLC

/s/ Adrian Kemp
Signature
Adrian Kemp, Company Secretary
Name/Title

Zeneca Inc.

/s/ David E. White
Signature
David E. White, Director and Treasurer
Name/Title

ATTENTION:
Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

6
JOINT FILING AGREEMENT

In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the persons named below agrees to the joint filing of a Statement on Schedule 13G (including amendments thereto) with respect to the common stock, $0.0001 par value per share, of Moderna, Inc., a Delaware corporation, and further agrees that this Joint Filing Agreement be included as an exhibit to such filings provided that, as contemplated by Rule 13d-1(k)(1)(ii), no person shall be responsible for the completeness or accuracy of the information concerning the other persons making this filing, unless such person knows or has reason to believe that such information is in accurate. This Joint Filing Agreement may be executed in any number of counterparts, all of which together shall constitute one and the same instrument.

January 30, 2019

AstraZeneca PLC

/s/ Adrian Kemp
Signature
Adrian Kemp, Company Secretary
Name/Title

Zeneca Inc.

/s/ David E. White
Signature
David E. White, Director and Treasurer
Name/Title

1